{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-009930","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.108297+00:00","generated_at":"2026-06-05T08:32:39.715163+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bionano amends convertible debt deal, redeems $27.7M of notes, cuts liquidity covenant to $25M","bullets":["Redeems entire $17M outstanding principal of Initial Private Placement Note at 115% for $19.55M; plus $1M increase to retirement fee.","Redeems $10.663M of Initial Registered Note at 115% for $12.26M; $24.337M principal remains outstanding.","Minimum liquidity covenant reduced from $50M to $25M; restricted cash requirement cut from $35M to $25M.","March 2024 partial redemption canceled; April payment delayed from April 1 to April 20, 2024.","Company gains immediate access to $30M in near-term liquidity, with up to $25M more as principal is retired."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-009930","json":"https://secwatch.observer/filing/0001140361-24-009930.json","markdown":"https://secwatch.observer/filing/0001140361-24-009930.md","text":"https://secwatch.observer/filing/0001140361-24-009930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000114036124009930/0001140361-24-009930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000114036124009930/ef20022651_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:32:39.715163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06f450d4b3287cf9bd2c7d08e0d2ca05f2f42d1d","claim":"Bionano Genomics, Inc. entered into Letter Agreement with High Trail Special Situations LLC valued at total redemption payment of $19,550,000 (effective 2024-02-27).","evidence_excerpt":"On February 27, 2024, the Company entered into a letter agreement (the “Letter Agreement”) with the Purchaser to (i) redeem (a) the entire outstanding principal amount under the Initial Private Placement Note of $17,000,000 from the Purchaser at a redemption price of 115% for a total redemption payment of $19,550,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036124009930/0001140361-24-009930-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"High Trail Special Situations LLC"},{"label":"Value","value":"total redemption payment of $19,550,000"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"},{"claim_id":"c9754a9dc79d0c258e14c14325809ccf9d357ed7","claim":"Bionano Genomics, Inc. entered into Amendment with High Trail Special Situations LLC (effective 2024-02-27).","evidence_excerpt":"Concurrent with the entry into the Letter Agreement, the Company and the Purchaser entered into an Amendment to Initial Registered Note (the “Amendment”), among other things, to (i) reduce the minimum liquidity covenant under the Initial Registered Note","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036124009930/0001140361-24-009930-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"High Trail Special Situations LLC"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}